Skip to content
Guide

Hereditary Cancer Testing in India: A Complete Guide to Risk

What hereditary cancer risk testing really tells you, which cancers are inherited, BRCA and gene panels, who should test, cost in India, and what results mean.

The Meridian Clinical Team Medically reviewed by Meridian Medical Review Board 3 min readUpdated 6 July 2026

Hereditary cancer testing looks for inherited gene changes that raise your lifetime risk of certain cancers, most commonly breast, ovarian, and colorectal. It does not diagnose cancer or make it certain. Only about 5–10% of all cancer is strongly hereditary. This guide explains what the test is, who it helps, and what a result means in India.

What "hereditary cancer risk" actually means

Most cancer is not inherited. It arises from a lifetime of random cell changes, ageing, and environment. But in a minority of families, a single gene variant is passed down that makes cancer more likely, and often earlier. Hereditary cancer testing looks specifically for these inherited variants.

The crucial distinction:

  • A predisposition means higher-than-average risk, not a diagnosis, and not certainty.
  • Many people who carry a risk variant never develop that cancer.
  • A negative result does not mean zero risk; everyone still carries ordinary population risk.

This is a hereditary cancer risk screen, a planning tool, not a cancer test.

Which cancers are hereditary?

Only some cancers have well-established inherited forms. The most understood are:

Cancer typeCommon genesSyndrome
Breast & ovarianBRCA1, BRCA2, PALB2Hereditary breast & ovarian cancer
Colorectal & uterineMLH1, MSH2, MSH6, PMS2Lynch syndrome
Multiple / young-onsetTP53Li-Fraumeni
StomachCDH1Hereditary diffuse gastric

A multi-gene panel tests many of these genes at once, which is why modern testing rarely looks at BRCA alone.

BRCA and multi-gene panels

BRCA1 and BRCA2 are the best-known cancer-risk genes. A woman who inherits a harmful BRCA variant has a substantially higher lifetime risk of breast and ovarian cancer than average, though estimates are ranges, not fixed numbers, and depend on the specific variant and family history.

Today, most laboratories run a panel covering BRCA plus other genes in one test, because family patterns don't always point to a single gene. Meridian uses next-generation sequencing (NGS) for its panels.

Who should consider testing

Testing makes the most sense when there is a genuine family signal. Consider it if you have:

  • Several close relatives with the same or related cancers (e.g. breast + ovarian, or colon + uterine).
  • A relative diagnosed young (breast or colon cancer under ~50).
  • A known cancer-risk variant already found in your family.
  • Certain ancestries with higher carrier rates (discuss with a counsellor).

If your family history is limited or unremarkable, the odds of a meaningful finding are low, and that is worth talking through before testing, not after.

The Indian context

Cancer genetics is still under-used in India despite rising cancer numbers. Access to genetic counselling is uneven, awareness is low, and families often carry undiagnosed hereditary risk across generations. Newer, affordable NGS panels are changing this, but the value still depends on interpreting results within your family and clinical picture, ideally with a genetic counsellor.

What your result means

  • Positive (pathogenic variant found): You carry an inherited variant linked to higher risk. This is a reason to discuss enhanced screening or prevention with a doctor, not a diagnosis. Close relatives may wish to consider testing too.
  • Negative: No known harmful variant was found. Reassuring, but you still carry ordinary population risk, and a strong family history may still warrant closer screening.
  • Variant of uncertain significance (VUS): A change was found whose effect isn't yet understood. It is generally not acted on medically and may be reclassified over time. A counsellor should explain this carefully.

Screening and management decisions belong with your clinicians, every result should be read alongside your personal and family history.

Cost and turnaround in India

At Meridian, an NGS hereditary cancer / carrier panel is around ₹15,000, run in a CAP-grade lab, with reports in about 14 working days. Every test includes a free doctor consultation so results are explained by a clinician rather than left to a PDF.

Explore specific questions

This is the overview. The articles below go deeper into the questions people actually search: what the test covers in India, what BRCA testing costs, and the honest answer to "my mother had breast cancer, am I at risk?"

This article is for education, not medical diagnosis. Genetic results describe risk and tendencies, not certainty. Always discuss testing and results with a qualified doctor.

Meridian test

Inherited Cancer Risk

Understand your inherited cancer risk early, so you and your doctor can plan the right care sooner.

₹15,000Learn about the test →

Frequently asked questions

No. The test identifies an inherited predisposition, a higher-than-average risk, not a diagnosis and not a certainty. Most people who carry a risk variant never develop that cancer, and most cancer (around 90–95%) is not hereditary at all. A result is a reason to plan screening with a doctor, not a verdict.

Start today

Your DNA won't change.
The decisions you make can.

The most personalized health plan you'll ever have is already inside you. Explore the tests and turn it into a longer, healthier life.